The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Talimogene laherparepvec: First in class oncolytic virotherapy
Open accessAbstract
Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherparepvec (TVEC) is a type I herpes simplex virus genetically modified to preferentially replicate in tumor cells, enhance antigen loading of MHC class I molecules and express granulocyte-macrophage colony-stimulating factor to increase tumor-antigen presentation by dendritic cells. It is presently the only oncolytic virus approved by the FDA with an indication for advanced melanoma based upon improved durable response rate in a randomized, phase III trial. Clinical trials are underway in melanoma investigating TVEC as neoadjuvant monotherapy and in combination with checkpoint inhibitors for unresectable disease as well as in an array of other malignancies. It is appropriate to review TVEC's biology mechanism of action, clinical indication and future directions as a prototype of the burgeoning class of oncolytic viruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two such agents have FDA approval: oncolytic viral therapy for advanced melanoma using talimogene laherparepvec (T-VEC) (146), and bacterial cancer therapy for high-risk, non-muscle invasive bladder cancer using live-attenuated Mycobacterium bovis (BCG vaccine) (147).”
From The microbiome and human cancer (2021) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“tumors before a response, as described with other forms of immunotherapy.(20,21)”
BackgroundPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 1×
“and OS compared to ipilimumab (anti-CTLA4) with fewer serious adverse events.(43) The addition of pembrolizumab to TVEC would theoretically allow efficient T-cell priming by”
BackgroundWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222 · cited 1×
“tumors before a response, as described with other forms of immunotherapy.(20,21)”
BackgroundOncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520 · cited 2×
“Twenty one patients with stage IIIB-IV M1c melanoma with injectable tumors and no prior systemic therapy received TVEC monotherapy at an initial dose of 10(6) PFU/mL followed by 10(8) PFU/mL every 2 weeks from week 3.(44) Pembrolizumab was given intravenously at 200 mg every 2 weeks beginning with the third TVEC dose…”
BackgroundMethodExperimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
PKR; a sentinel kinase for cellular stress
Williams, B. R. (1999) · Oncogene · doi:10.1038/sj.onc.1203127 · Cited by 820 · cited 1×
“The PKR pathway is critical for regulating aberrant cell proliferation and intrinsic cellular antiviral responses.(4) In normal”
BackgroundLiu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803 · cited 1×
“When GM-CSF was incorporated into the virus, regression of both injected and uninjected tumors occurred, consistent with a systemic antitumor immune response.(12) Furthermore, mice were protected from rechallenge with the same tumor cells, indicating induction of durable anti-tumor memory responses.”
BackgroundHe, B., Gross, M., & Roizman, B. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.843 · Cited by 751
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711 · cited 2×
“Murine models demonstrated tumor infiltration by CD8C T -cells in both injected and noninjected metastases.(18) Melanoma patients treated with TVEC demonstrated accumulation of melanoma antigen specific CD8C T-cells within injected lesions associated with a reduction in CD4C FoxP3C regulatory T-cells and CD14C myeloid…”
BackgroundResult
Research works printed but not linked: 8
- Coffin RS, 1996, Gene Ther, 3, 886
- Kaufman HL, 2016, J Immuno Therapy Cancer, 6, 46
- Kaufman H, 2015, ASCO
- Robert C, J Clin Oncol, 2017
- Long G, J Clin Oncol, 2017
- Leung ACF, J Clin Oncol, 2017
- Robert C, 2017, Am J Health Syst Pharm, 73, 193
- Chang KJ, 2012, J Clin Oncol, 30
Cited by
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020) · Current Oncology · doi:10.3747/co.27.5223 · Cited by 954
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
The immunology of renal cell carcinoma
Díaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 442
Metadata
- Authors
- Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G.
- Affiliations
- University of Alabama at Birmingham (US)
- Corresponding author
- Conry, Robert M.
- ORCID
- Conry, Robert M.
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2018-02-22
- Volume
- 14
- Issue
- 4
- Pages
- 839-846
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- PMC
- PMC5893211
- OpenAlex
- W2793196876
- Cited by
- 335
- References
- 49
- Citations by year
- 2026: 17 · 2025: 32 · 2024: 31 · 2023: 30 · 2022: 53 · 2021: 70 · 2020: 63 · 2019: 34 · 2018: 4
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Human Vaccines & Immunotherapeutics (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Keywords
- talimogene laherparepvec, oncolytic virotherapy, herpes simplex virus type 1, advanced melanoma, MHC class I antigen presentation, dendritic cells, GM-CSF, tumor immunology, neoadjuvant therapy, immune checkpoint inhibitors, combination therapy
- MeSH terms
- Animals, Antigens, Neoplasm, Dendritic Cells, Humans, Immunotherapy, Randomized Controlled Trials as Topic, Herpesvirus 1, Human, Oncolytic Virotherapy, Oncolytic Viruses
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Talimogene laherparepvec: First in class oncolytic virotherapy. https://app.cochat.ai/papers/10.1080/21645515.2017.1412896
- The paper
- Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018). Talimogene laherparepvec: First in class oncolytic virotherapy. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2017.1412896
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.